Home » Stocks » REPL

Replimune Group, Inc. (REPL)

Stock Price: $44.14 USD -0.75 (-1.67%)
Updated Oct 28, 2020 11:14 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.78B
Revenue (ttm) n/a
Net Income (ttm) -60.61M
Shares Out 40.29M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $44.14
Previous Close $44.89
Change ($) -0.75
Change (%) -1.67%
Day's Open 44.37
Day's Range 42.58 - 45.04
Day's Volume 51,732
52-Week Range 8.58 - 47.96

More Stats

Market Cap 1.78B
Enterprise Value 1.56B
Earnings Date (est) Nov 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 40.29M
Float 19.55M
EPS (basic) -1.66
EPS (diluted) -1.67
FCF / Share -1.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 933,529
Short Ratio 0.76
Short % of Float 4.78%
Beta 3.23
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.55
Revenue n/a
Operating Income -63.12M
Net Income -60.61M
Free Cash Flow -69.17M
Net Cash 220.25M
Net Cash / Share 5.47
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -15.85%
ROE -29.71%
ROIC -29.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(11.87% upside)
Current: $44.14
Target: 49.38
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-56.20-30.95-19.23-9.65
Net Income-52.63-30.83-19.70-7.70
Shares Outstanding34.2623.204.984.97
Earnings Per Share-1.54-1.33-3.96-1.55
Operating Cash Flow-60.55-25.38-16.01-7.08
Capital Expenditures-6.54-2.60-0.14-0.24
Free Cash Flow-67.09-27.98-16.15-7.32
Cash & Equivalents17013661.6320.67
Total Debt41.796.56--
Net Cash / Debt12812961.6320.67
Book Value184138-28.07-11.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Replimune Group, Inc.
Country United States
Employees 122
CEO Philip Astley-Sparke

Stock Information

Ticker Symbol REPL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: REPL
IPO Date July 20, 2018


Replimune Group, a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.